Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), KalVista Pharmaceuticals (KALV) and TScan Therapeutics (TCRX)

Tipranks - Tipranks - Fri Apr 17, 6:14AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Jazz Pharmaceuticals (JAZZ), KalVista Pharmaceuticals (KALV) and TScan Therapeutics (TCRX) with bullish sentiments.

Claim 30% Off TipRanks

Jazz Pharmaceuticals (JAZZ)

Needham analyst Ami Fadia maintained a Buy rating on Jazz Pharmaceuticals today and set a price target of $235.00. The company’s shares closed last Wednesday at $199.33.

According to TipRanks.com, Fadia is a 5-star analyst with an average return of 29.2% and a 55.5% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, MapLight Therapeutics, Inc., and Praxis Precision Medicines. ;'>

Jazz Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $230.42, a 14.1% upside from current levels. In a report issued on April 9, Wells Fargo also maintained a Buy rating on the stock with a $250.00 price target.

See today’s best-performing stocks on TipRanks >>

KalVista Pharmaceuticals (KALV)

Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on KalVista Pharmaceuticals today and set a price target of $32.00. The company’s shares closed last Wednesday at $20.86.

According to TipRanks.com, Ahmad is a 4-star analyst with an average return of 3.5% and a 53.7% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Bicara Therapeutics Inc., and Apellis Pharmaceuticals. ;'>

Currently, the analyst consensus on KalVista Pharmaceuticals is a Strong Buy with an average price target of $35.57, implying a 75.0% upside from current levels. In a report issued on April 6, JonesTrading also reiterated a Buy rating on the stock with a $39.00 price target.

TScan Therapeutics (TCRX)

In a report released today, Gil Blum from Needham maintained a Buy rating on TScan Therapeutics, with a price target of $6.00. The company’s shares closed last Wednesday at $1.07.

According to TipRanks.com, Blum is a 5-star analyst with an average return of 11.2% and a 42.4% success rate. Blum covers the Healthcare sector, focusing on stocks such as Artiva Biotherapeutics, Inc., Recursion Pharmaceuticals, and Mereo Biopharma Group Plc. ;'>

Currently, the analyst consensus on TScan Therapeutics is a Strong Buy with an average price target of $6.00, which is a 471.4% upside from current levels. In a report issued on April 9, H.C. Wainwright also maintained a Buy rating on the stock with a $7.00 price target.

Read More on JAZZ:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).